DavidRAndesMD

Physician

Dr. Andes is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
600 Highland Ave
Madison, WI 53792
Phone+1 608-263-0943

Fax+1 608-263-9103

University of Wisconsin Hospitals and ClinicsFellowship, Infectious Disease, 1996 - 1999
University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1992 - 1996
University of Missouri-Columbia School of MedicineClass of 1992

Association of American Physicians Association of American Physicians, 2018
American Academy of Microbiology - Fellow American Academy of Microbiology, 2017
Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011
Elected Member The American Society for Clinical Investigation, 2010
Join now to see all

PubMed

Characterizing extracellular vesicles of human fungal pathogens.
Marcio L Rodrigues, Guilhem Janbon, Richard J O'Connell, Thi-Thu-Huyen Chu, Robin C May
Nature Microbiology. 2025-03-27
Vesicle inhibition reducesbiofilm resistance.
Min-Ju Kim, Robert Zarnowski, Ryley Jones, Jeniel E Nett, David Andes
Antimicrobial Agents and Chemotherapy. 2025-03-26
1 citations
Structure-guided optimization of small molecules targeting Yck2 as a strategy to combat Candida albicans.
Emily Puumala, Meganathan Nandakumar, Bonnie Yiu, Peter J Stogios, Benjamin G Strickland
Nature Communications. 2025-03-04

The Fight Against FungiFebruary 28th, 2021
UWCCC Small Molecule Screening Facility Validates the Lumit™ Dx SARS-CoV-2 Immunoassay for High-Throughput SARS-CoV-2 Antibody ScreeningJanuary 4th, 2021
Hospitals Stretched Beyond 'Reasonable Limit' as Number of COVID-19 Patients Reaches 100,000December 3rd, 2020
Join now to see all

Vesicle-mediated drug resistance of Candida albicans biofilmUNIVERSITY OF WISCONSIN-MADISON2008–2029
Symbiotic-based discovery of turbinmicin, a safe and selective antifungal against resistant fungiUNIVERSITY OF WISCONSIN-MADISON2022–2027
Molecular Mycology: Current Approaches to Fungal Pathogenesis (MoMy) Training CourseMARINE BIOLOGICAL LABORATORY2021–2026
Molecular Mycology: Current Approaches to Fungal Pathogenesis (MoMy) Training CourseMARINE BIOLOGICAL LABORATORY2021–2026
Molecular Mycology: Current Approaches to Fungal Pathogenesis (MoMy) Training CourseMARINE BIOLOGICAL LABORATORY2021–2026
Molecular Mycology: Current Approaches to Fungal Pathogenesis (MoMy) Training CourseMARINE BIOLOGICAL LABORATORY2021–2026
Novel antimicrobials targeting MDR pathogens from animal microbial symbiontsUNIVERSITY OF WISCONSIN-MADISON2019–2025
Development of non-toxic amphotericin B derivatives targeting invasive fungal infectionsUNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN2018–2025
Training In The Use Of Bruker And Varian Spectrometers And NMRNational Center For Research Resources2010
Fluconazole-Biofilm Matrix In Candida AlbicansNational Center For Research Resources2010
Pharmacodynamics In Antifungal ResistanceNational Institute Of Allergy And Infectious Diseases2001–2005